Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Clinical Pharmacology and Therapeutics
|
January 17, 2019
Innovation for Generic Drugs: Science and Research Under the Generic Drug User Fee Amendments of 2012
Robert A Lionberger
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics
|
August 22, 2002
Viscosity of bimodal and polydisperse colloidal suspensions
Robert A Lionberger
The AAPS Journal
|
May 1, 2008
FDA critical path initiatives: opportunities for generic drug development
Robert A Lionberger
Clinical Pharmacology and Therapeutics
|
January 17, 2020
Generics 2030: Where Are We Heading in 2030 for Generic Drug Science, Research, and Regulation?
Lei Zhang, Robert A Lionberger
The AAPS Journal
|
May 18, 2016
Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products
Stephanie H Choi, Robert A Lionberger
Molecular Pharmaceutics
|
July 21, 2005
Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates
Hyojong Kwon, Robert A Lionberger, Lawrence X Yu
Therapeutic Delivery
|
June 7, 2013
Innovative approaches for demonstration of bioequivalence: the US FDA perspective
Xinyuan Zhang, Nan Zheng, Robert A Lionberger, et al.
The AAPS Journal
|
January 6, 2011
Utility of physiologically based absorption modeling in implementing Quality by Design in drug development
Xinyuan Zhang, Robert A Lionberger, Barbara M Davit, et al.
The AAPS Journal
|
May 10, 2008
Quality by design: concepts for ANDAs
Robert A Lionberger, Sau Lawrence Lee, Laiming Lee, et al.
Pharmaceutical Research
|
January 27, 2012
Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations
Robert A Lionberger, Andre S Raw, Stephanie H Kim, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Clinical Pharmacology and Therapeutics
|
January 17, 2019
Innovation for Generic Drugs: Science and Research Under the Generic Drug User Fee Amendments of 2012
Robert A Lionberger
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics
|
August 22, 2002
Viscosity of bimodal and polydisperse colloidal suspensions
Robert A Lionberger
The AAPS Journal
|
May 1, 2008
FDA critical path initiatives: opportunities for generic drug development
Robert A Lionberger
Clinical Pharmacology and Therapeutics
|
January 17, 2020
Generics 2030: Where Are We Heading in 2030 for Generic Drug Science, Research, and Regulation?
Lei Zhang, Robert A Lionberger
The AAPS Journal
|
May 18, 2016
Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products
Stephanie H Choi, Robert A Lionberger
Molecular Pharmaceutics
|
July 21, 2005
Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates
Hyojong Kwon, Robert A Lionberger, Lawrence X Yu
Therapeutic Delivery
|
June 7, 2013
Innovative approaches for demonstration of bioequivalence: the US FDA perspective
Xinyuan Zhang, Nan Zheng, Robert A Lionberger, et al.
The AAPS Journal
|
January 6, 2011
Utility of physiologically based absorption modeling in implementing Quality by Design in drug development
Xinyuan Zhang, Robert A Lionberger, Barbara M Davit, et al.
The AAPS Journal
|
May 10, 2008
Quality by design: concepts for ANDAs
Robert A Lionberger, Sau Lawrence Lee, Laiming Lee, et al.
Pharmaceutical Research
|
January 27, 2012
Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations
Robert A Lionberger, Andre S Raw, Stephanie H Kim, et al.
Page
of 2